Jasper Therapeutics (JSPR) Long-Term Deferred Tax (2019 - 2023)
Jasper Therapeutics (JSPR) posted quarterly Long-Term Deferred Tax of $47.0 million for Q4 2023, up 8239.79% year-over-year from $563000.0 in Q4 2022, and up 8239.79% quarter-over-quarter from $563000.0 in Q4 2022.
Jasper Therapeutics (JSPR) Long-Term Deferred Tax (2019 - 2023) Analysis & Trends
Jasper Therapeutics' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $47.0 million for Q4 2023.
- In Q4 2023, Long-Term Deferred Tax rose 8239.79% year-over-year to $47.0 million; the TTM figure through Dec 2023 stood at $47.0 million (up 8239.79% YoY), while the FY2023 annual figure was $47.0 million, up 8239.79% from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $47.0 million, up from $563000.0 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $47.0 million in Q4 2023, with the low at $12389.0 in Q4 2019.
- The 5-year median for Long-Term Deferred Tax is $326000.0 (2021), against an average of $7.1 million.
- The sharpest annual moves came in 2020 and 2021: Long-Term Deferred Tax jumped 64360.41% in 2020, then slumped 95.96% in 2021.
- Jasper Therapeutics' Long-Term Deferred Tax stood at $12389.0 in 2019, then surged by 64360.41% to $8.0 million in 2020, then plunged by 95.96% to $323000.0 in 2021, then surged by 74.3% to $563000.0 in 2022, then surged by 8239.79% to $47.0 million in 2023.
- Business Quant data shows JSPR's Long-Term Deferred Tax at $47.0 million in Q4 2023, $563000.0 in Q4 2022, and $323000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Jasper Therapeutics | 20.09 Mn | 20.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 46.95 Mn |
| Dec 31, 2022 | 563,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Jun 30, 2021 | 329,000.00 |
| Dec 31, 2020 | 7.99 Mn |
| Sep 30, 2020 | 144,000.00 |
| Jun 30, 2020 | 108,000.00 |
| Dec 31, 2019 | 12,389.00 |